Business Context and Reporting Period
Company: Immunocore Holdings Plc
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Immunocore is a commercial-stage biotechnology company developing immunomodulating medicines using its proprietary ImmTAX platform. Its lead product, KIMMTRAK (tebentafusp), is approved in 39 countries for the treatment of unresectable or metastatic uveal melanoma (mUM) and has been commercially launched in 30 countries. The company maintains a pipeline in oncology (e.g., brenetafusp), infectious diseases (e.g., HIV, HBV), and autoimmune diseases.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue from sale of therapies, net | $400,016 | $309,989 |
| Total Revenue | $400,016 | $310,202 |
| Net Loss | $(35,514) | $(51,087) |
| Research & Development Expenses | $(274,869) | $(222,151) |
| Selling, General & Administrative Expenses | $(165,413) | $(155,781) |
| Cash and Cash Equivalents (Year End) | $467,709 | $455,731 |
| Marketable Securities (Year End) | $396,444 | $364,645 |
| Working Capital | $750,045 | $717,683 |
| Convertible Senior Notes (Principal) | $402,500 | $402,500 |
Note: The company reported a net loss of $35.5 million for 2025, an improvement from $51.1 million in 2024. Revenue grew 29% year-over-year, driven by increased sales in the United States and Europe.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue from therapy sales increased by $90.0 million (29%) to $400.0 million. This was driven by volume growth in the U.S. ($257.0 million) and Europe ($131.4 million). A $6.0 million net decrease in estimated reserves related to prior periods also positively impacted 2025 revenue.
- Expense Increases: R&D expenses rose by $52.7 million (24%) to $274.9 million, primarily due to increased costs for "all other external clinical and preclinical costs" ($36.0 million increase) related to autoimmune programs and continued advancement of Phase 3 trials for tebentafusp. SG&A expenses increased by $9.6 million to $165.4 million to support global commercial expansion.
- Interest Income/Expense: Interest income decreased by $9.1 million to $16.5 million due to lower interest rates on money market funds. Interest expense decreased by $6.6 million to $12.2 million following the full repayment of the Pharmakon loan in November 2024.
- Tax Impact: The company recorded a $14.7 million deferred tax expense in 2025 due to a valuation allowance on U.S. deferred tax assets, reversing a benefit recorded in 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Strategic Priorities for 2026: Focus on growing KIMMTRAK sales, preparing for new melanoma indications (TEBE-AM and ATOM trials), expanding beyond melanoma into other tumor types (ovarian, lung, colorectal), and advancing infectious disease and autoimmune candidates.
- Clinical Milestones:
- TEBE-AM (Advanced Melanoma): Enrollment expected to complete in H1 2026; topline data expected H2 2026.
- PRISM-MEL-301 (Brenetafusp): Ongoing Phase 3 trial in first-line advanced cutaneous melanoma.
- Autoimmune: Phase 1 trial for IMC-S118AI (Type 1 Diabetes) expected to begin in H1 2026.
- Infectious Disease: Data readouts for HIV (IMC-M113V) and HBV (IMC-I109V) expected in H2 2026.
- Liquidity: Management expects existing cash, cash equivalents, marketable securities, and anticipated revenue to fund operations for at least 12 months from the filing date.
Risks and Contingencies
- Profitability: The company has incurred losses since inception and expects to continue incurring significant operating losses. It has an accumulated deficit of $831.3 million as of December 31, 2025.
- Regulatory and Clinical: Risks include failure to obtain regulatory approval for new indications, delays in clinical trials, and potential safety issues (e.g., cytokine release syndrome warnings for KIMMTRAK).
- Manufacturing: Reliance on third-party contract manufacturers (CMOs). A global recall of one batch of KIMMTRAK was initiated in June 2025 due to stability testing; management does not expect a material impact on supply or financials.
- Reimbursement and Pricing: Revenue is subject to rebates and chargebacks. Significant judgment is required to estimate these deductions, particularly in European markets where pricing negotiations occur. A 20% change in these estimates could impact net revenue by approximately $2.0 million.
- Debt: The company has $402.5 million in Convertible Senior Notes due 2030. Conversion could dilute shareholders.
Key Facts for Investor Verification
- Revenue Concentration: Four customers accounted for approximately 23%, 23%, 17%, and 18% of 2025 revenue from therapy sales.
- Geographic Mix: 64% of 2025 revenue came from the United States, 33% from Europe, and 3% from International markets.
- Patent Expiry: The granted U.S. patent for KIMMTRAK, including patent term extension, is set to expire in 2035.
- Collaboration Agreements:
- BMS: Collaboration for PRISM-MEL-301 trial (brenetafusp + nivolumab); no monetary consideration transferred.
- Gates Foundation: Agreement requires development of neglected disease candidates (HIV); includes potential share buy-back obligations in default scenarios.
- Executive Departures: Dr. David Berman (EVP, R&D) and Tina St. Leger (CHRO) announced departures effective early 2026.